Home > Insider Trading > Filing (0001237899-20-000001)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
872589	Regeneron Pharmaceuticals Inc.	REGN	Pharmaceutical Preparations (2834)	133444607

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1225471	L George Sing	777 Old Saw Mill River Road Tarrytown NY 10591		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-01-02	15,000	$24.41	130,095	No	4	M	Direct
Common Stock	Disposition	2020-01-02	15,000	$371.98	115,095	No	4	S	Direct
Common Stock	Acquisiton	2020-01-02	320	$0.00	115,415	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2020-01-02	15,000	$0.00	15,000	$24.41
Common Stock	Non-Qualified Stock Option (right to buy)	Acquisiton	2020-01-02	4,361	$0.00	4,361	$374.12

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2020-01-04	No	4	M	Direct
4,361		2030-01-02	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,000	Indirect	by Spouse
Common Stock	4,500	Indirect	by Spouse/Cust Son
Common Stock	10,000	Indirect	by Trust for Son

Footnotes

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 15,000 shares of the Issuer's common stock on January 2, 2020 at prices ranging from $371.98 to $371.99. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2020.
Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.